Daily versus Twice Daily Nifedipine for Blood Pressure Control in Pregnancy and Postpartum

The objective of this study was to compare 60 mg daily (QD) extended released (XR) nifedipine to 30 mg twice daily (BID) for blood pressure (BP) control antepartum and postpartum.This is a retrospective chart review conducted at the Mount Sinai Health System. Patients admitted from January 1, 2015, to April 30, 2021, diagnosed with a hypertensive disorder of pregnancy, who received nifedipine XR 30 mg BID or 60 mg QD for intrapartum or postpartum BP control were included. The primary outcome was the need for up-titration (i.e., the need for an increase in nifedipine dose or addition of another antihypertensive) after reaching one of the study doses (30 mg BID or 60 mg QD). Patients were excluded if they had preexisting renal disease or were already on oral antihypertensives. In a 1:1 ratio between single- and twice-daily dosing groups, the sample size needed to detect a 20% difference in up-titration rate to achieve 0.80 power is 97 patients per group, for a total of 194 patients. This is based on a Pearson chi-square test with a significance level of 0.05.A total of 237 patients were included, 139 (59%) received 30 mg BID and 98 (41%) 60 mg QD. There was no statistically significant difference in the need for an increase in nifedipine dose or addition of another oral antihypertensive agent between those receiving 30 mg BID versus 60 mg QD (33.8 vs. 35.7%; adjusted odds ratio [aOR], 95% confidence interval [CI]: 0.90 [0.50-1.60]; <i>p</i> = 0.71). There was no difference in the need for emergency hypertensive treatment after reaching the study dose (<i>p</i> = 0.19) or readmission for BP control between groups (<i>p</i> > 0.99).These findings suggest that BID dosing does not confer better BP control in the antepartum or postpartum periods. Thus, daily dosing is reasonable and may be preferable for patient convenience and compliance. · Nifedipine metabolism may increase in pregnancy.. · nifedipine 30 mg BID versus 60 mg QD were compared.. · There was no difference in the need for additional medication.. · There was no difference in the need for readmission.. · Daily dosing may be preferable for convenience..

Authors

Institutions

Publication Details

Journal
American Journal of Perinatology
Published
2024-11-26
DOI
https://doi.org/10.1055/a-2486-8840
Primary Topic
Pregnancy and Medication Impact
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Daily versus Twice Daily Nifedipine for Blood Pressure Control in Pregnancy and Postpartum

Kelly Wang, Isabelle C. Band, Jessica A. Peterson, Angela T Bianco
American Journal of Perinatology
Pregnancy and Medication Impact
article

Daily versus Twice Daily Nifedipine for Blood Pressure Control in Pregnancy and Postpartum

Kelly Wang, Isabelle C. Band, Jessica A. Peterson, Angela T Bianco
article en

Abstract

The objective of this study was to compare 60 mg daily (QD) extended released (XR) nifedipine to 30 mg twice daily (BID) for blood pressure (BP) control antepartum and postpartum.This is a retrospective chart review conducted at the Mount Sinai Health System. Patients admitted from January 1, 2015, to April 30, 2021, diagnosed with a hypertensive disorder of pregnancy, who received nifedipine XR 30 mg BID or 60 mg QD for intrapartum or postpartum BP control were included. The primary outcome was the need for up-titration (i.e., the need for an increase in nifedipine dose or addition of another antihypertensive) after reaching one of the study doses (30 mg BID or 60 mg QD). Patients were excluded if they had preexisting renal disease or were already on oral antihypertensives. In a 1:1 ratio between single- and twice-daily dosing groups, the sample size needed to detect a 20% difference in up-titration rate to achieve 0.80 power is 97 patients per group, for a total of 194 patients. This is based on a Pearson chi-square test with a significance level of 0.05.A total of 237 patients were included, 139 (59%) received 30 mg BID and 98 (41%) 60 mg QD. There was no statistically significant difference in the need for an increase in nifedipine dose or addition of another oral antihypertensive agent between those receiving 30 mg BID versus 60 mg QD (33.8 vs. 35.7%; adjusted odds ratio [aOR], 95% confidence interval [CI]: 0.90 [0.50-1.60]; <i>p</i> = 0.71). There was no difference in the need for emergency hypertensive treatment after reaching the study dose (<i>p</i> = 0.19) or readmission for BP control between groups (<i>p</i> > 0.99).These findings suggest that BID dosing does not confer better BP control in the antepartum or postpartum periods. Thus, daily dosing is reasonable and may be preferable for patient convenience and compliance. · Nifedipine metabolism may increase in pregnancy.. · nifedipine 30 mg BID versus 60 mg QD were compared.. · There was no difference in the need for additional medication.. · There was no difference in the need for readmission.. · Daily dosing may be preferable for convenience..

American Journal of PerinatologyVol. 42(10)
Mount Sinai Hospital (US), Icahn School of Medicine at Mount Sinai (US)
Good health and well-being
Openalex Percentile: Top 67%
Pregnancy and Medication Impact
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.